Skip to main content

Clinical Trial Search Results

A scientist pointing to an image of a DNA chain.

Clinical Trial Search Results

Showing 154-162 out of 311 results.
NCT04073563

Prospective, Randomized, Controlled, Blinded Pivotal Study In Subjects Undergoing A Transforaminal Lumbar Interbody Fusion (TLIF) At One Or Two Levels Using Infuse™ Bone Graft With an Intervertebral Body Fusion Device and Posterior Supplemental Fixation For The Treatment Of Symptomatic Degenerative Disease Of The Lumbosacral Spine

Icon for trial | Prospective, Randomized, Controlled, Blinded Pivotal Study In Subjects Undergoing A Transforaminal Lumbar Interbody Fusion (TLIF) At One Or Two Levels Using Infuse™ Bone Graft With an Intervertebral Body Fusion Device and Posterior Supplemental Fixa

This study is currently enrolling.

The purpose of this study is to evaluate the Infuse™ Bone Graft in combination with other spinal devices and autograft bone (your own bone) to see if it is safe and effective when used in a TLIF surgery. Two different amounts o ...

NCT05685004

Randomized controlled Phase 2b clinical trial to evaluate the safety and efficacy of TVI-Brain-1 combined with conformal radiotherapy and temozolomide compared to standard therapy as a treatment for newly diagnosed O6-methylguanine methyltransferase negative (MGMT unmethylated) grade 4 astrocytoma (glioblastoma multiforme; glioblastoma; GBM).

Icon for trial | TVI AST 008 Randomized controlled Phase 2b clinical trial to evaluate the safety and efficacy of TVI-Brain-1 combined with conformal radiotherapy and temozolomide compared to standard therapy as a treatment for newly diagnosed O6-methylguanine methyltrans

This study is currently enrolling.

This clinical trial is being performed because there is a need for safer and more effective treatments for glioblastomas. The purpose of this specific clinical study is to determine how safe and effective TVI-Brain-1 would be a ...

REIMAGINE 4 - Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. once weekly versus tirzepatide 15 mg s.c. once weekly in participants with type 2 diabetes inadequately controlled on metformin with or withouT an SGLT2 inhibitor

Icon for trial | REIMAGINE 4 - Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. once weekly versus tirzepatide 15 mg s.c. once weekly in participants with type 2 diabetes inadequately controlled on metformin with or withou

This study is currently enrolling.

Study Purpose: The purpose of this study is to look at how much a new investigational medicine called CagriSema lowers blood sugar and body weight in people with type 2 diabetes compared to another type 2 diabetes medicine call ...